So far, the concept to develop an HBPL based on an MC1R-specific peptide ([Cys3,4,10, DPhe7, Arg11]αMSH3-13) and an integrin αvβ3-affine peptide (c(RGDyD) (cyclic Arg-Gly-Asp-DTyr-Asp)) has only been described once for the radiotracer 99mTc-RGD-Lys-(Arg11)CCMSH intended for tumor therapy driven by caspase-3-induced apoptosis induction [31]. The gene discussed is MC1R; the disease is neoplasm.